Why a Zapped Age Spot Can Come Back Darker: The PIH Problem Explained

One of the most frustrating outcomes in pigment treatment is predictable in hindsight: a patient has a flat brown age spot lasered off, the crust falls away, the skin looks clear for a week or two, and then a darker, blurrier patch develops in the same location. This is not the original lentigo returning. In most cases it is post-inflammatory hyperpigmentation, usually shortened to PIH, and it is the single most common complication reported after laser and intense pulsed light treatment of solar lentigines.

Understanding why it happens requires separating two different pigment problems. A solar lentigo, the classic age spot, is a discrete lesion where chronic ultraviolet exposure has produced a localized increase in melanocyte activity and, in many lesions, elongated rete ridges packed with melanin. PIH is different. It is a diffuse, reactive process. Any inflammation in the skin, whether from a burn, a pimple, a scratch, or a laser pulse, releases inflammatory mediators including prostaglandins and leukotrienes. These signaling molecules stimulate nearby melanocytes to produce more melanin. If the inflammation also damages the basal layer of the epidermis, melanin can drop down into the dermis, where it is engulfed by immune cells called melanophages and can persist for many months.

The irony is built into the treatment itself. Pigment lasers work through selective photothermolysis: a wavelength absorbed preferentially by melanin delivers energy fast enough to shatter or heat pigment-containing structures before that heat spreads to surrounding tissue. But controlled thermal injury is still injury. The same pulse that destroys the lentigo triggers the inflammatory cascade that can drive PIH. The question is never whether inflammation occurs, only whether it stays below the threshold that provokes a rebound pigment response in that particular patient.

Who is most at risk. Skin phototype is the dominant variable. In lighter phototypes, roughly Fitzpatrick I to II, PIH after appropriate laser settings is uncommon. In phototypes III to VI, published rates after Q-switched laser treatment of lentigines have ranged widely, with some East Asian cohorts reporting PIH in a quarter to nearly half of treated patients. The mechanism is straightforward: more baseline melanin means more competing chromophore in normal skin surrounding the lesion, so the laser heats healthy tissue more, and melanocytes in darker phototypes tend to respond to inflammation with a more vigorous pigment output. Other risk factors include recent tanning, treatment during high UV seasons, aggressive fluences, picking at post-treatment crusts, and a personal history of PIH from acne or minor wounds, which is a useful screening question that patients can answer themselves.

What actually lowers the odds. Several strategies have reasonable mechanistic and clinical support. First, device and setting selection matters. Longer wavelengths such as 1064 nm penetrate deeper and are absorbed less avidly by epidermal melanin than 532 nm or IPL, which makes them relatively safer in darker phototypes, though sometimes less efficient at clearing superficial lentigines. Picosecond lasers deliver energy in pulses short enough to rely more on photoacoustic fragmentation than heat, and comparative studies suggest a lower, though not zero, PIH rate versus older nanosecond devices. Second, a test spot in an inconspicuous area, evaluated four to six weeks later, is a low-cost way to preview an individual's inflammatory response before committing the whole face. Third, strict photoprotection before and after treatment is not optional. UV exposure independently activates melanocytes, and stacking that stimulus on top of laser-induced inflammation is the classic setup for rebound darkening. Broad-spectrum sunscreen and, increasingly, attention to visible light protection with tinted iron oxide formulations are relevant, because visible light alone can induce pigmentation in phototypes III and above.

Some clinicians also use pre-treatment or post-treatment topical regimens, most commonly hydroquinone or non-hydroquinone tyrosinase inhibitors such as azelaic acid, to quiet melanocyte activity around the treatment window. The evidence base here is mixed and study designs vary, but the mechanistic logic, reducing the pigment cell's capacity to overreact, is sound, and the approach is common in higher-risk phototypes.

If PIH happens anyway. The most important message is that epidermal PIH usually fades on its own over three to twelve months as normal keratinocyte turnover carries the excess melanin upward and out. Topical lightening agents, gentle retinoids, and disciplined sun protection can shorten that timeline. Dermal PIH, where melanin sits inside melanophages below the basement membrane, is slower and more stubborn, and paradoxically the worst thing to do is to fire more aggressive laser energy at it quickly, since that risks compounding the inflammation. Low-fluence approaches, patience, and topical therapy are the usual first line.

The practical takeaway: PIH after age spot treatment is not a sign the procedure failed or was done carelessly, though technique matters. It is a known, mechanistically well-understood risk that scales with baseline pigmentation and inflammation. Patients with medium to deep skin tones should expect a conversation about wavelength choice, test spots, seasonal timing, and photoprotection before any device touches a lentigo. If that conversation does not happen, it is reasonable to ask why.